FXYD1

Across TCGA pan-cancer cohorts, FXYD1 RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of FXYD1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where FXYD1 RNA is repressed in tumor relative to normal tissue. In most cancer types FXYD1 is over-expressed in tumor, although a few such as BLCA and LUAD show the opposite, repressed pattern.

BLCA, LUAD, and KICH are the cancer types where FXYD1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FXYD1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	−2.321	<.001	12	view →
LUAD	Female	III,IV	−2.554	<.001	11	view →
KICH	Female	All	−1.811	<.001	11	view →
COAD	Male	II,III,IV	−1.724	<.001	11	view →
THCA	Male	III,IV	−1.240	<.001	10	view →
LIHC	Female	All	−3.245	<.001	9	view →
LUSC	Male	III,IV	−2.772	<.001	9	view →
STAD	Female	All	−1.790	<.001	9	view →
HNSC	Male	All	−1.549	<.001	8	view →
READ	Female	All	−2.236	<.001	7	view →
KIRP	Male	All	−0.966	<.001	7	view →
UCEC	All	III,IV	−3.651	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 17 lineages.

FXYD1–BLCA

Open the BLCA breakdown →